Jennison Associates LLC Invests $3.49 Million in Guardian Pharmacy Services, Inc. $GRDN
by Doug Wharley · The Cerbat GemJennison Associates LLC purchased a new position in shares of Guardian Pharmacy Services, Inc. (NYSE:GRDN – Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 115,961 shares of the company’s stock, valued at approximately $3,489,000. Jennison Associates LLC owned approximately 0.18% of Guardian Pharmacy Services as of its most recent SEC filing.
Other hedge funds also recently made changes to their positions in the company. State of Alaska Department of Revenue bought a new position in shares of Guardian Pharmacy Services during the 3rd quarter worth approximately $30,000. Ameritas Investment Partners Inc. grew its stake in shares of Guardian Pharmacy Services by 26.5% during the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,647 shares of the company’s stock worth $43,000 after acquiring an additional 345 shares in the last quarter. Raymond James Financial Inc. bought a new position in shares of Guardian Pharmacy Services during the 2nd quarter worth approximately $43,000. State of Wyoming bought a new position in shares of Guardian Pharmacy Services during the 2nd quarter worth approximately $58,000. Finally, Parkside Financial Bank & Trust grew its stake in shares of Guardian Pharmacy Services by 70.5% during the 3rd quarter. Parkside Financial Bank & Trust now owns 3,248 shares of the company’s stock worth $85,000 after acquiring an additional 1,343 shares in the last quarter.
Insiders Place Their Bets
In related news, Director Thomas J. Salentine, Jr. sold 3,570,677 shares of the company’s stock in a transaction dated Friday, March 20th. The shares were sold at an average price of $29.68, for a total value of $105,977,693.36. Following the transaction, the director owned 4,469,316 shares in the company, valued at approximately $132,649,298.88. This represents a 44.41% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Kendall Forbes sold 346,672 shares of the company’s stock in a transaction dated Friday, March 20th. The shares were sold at an average price of $29.68, for a total transaction of $10,289,224.96. Following the completion of the transaction, the insider owned 453,256 shares in the company, valued at approximately $13,452,638.08. This trade represents a 43.34% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 9,726,405 shares of company stock worth $288,679,700 in the last 90 days. Corporate insiders own 32.96% of the company’s stock.
Guardian Pharmacy Services Price Performance
Shares of Guardian Pharmacy Services stock opened at $37.45 on Monday. The company has a market capitalization of $2.37 billion, a price-to-earnings ratio of 48.63, a P/E/G ratio of 2.48 and a beta of 0.09. The business has a fifty day simple moving average of $35.85 and a two-hundred day simple moving average of $32.03. Guardian Pharmacy Services, Inc. has a 1 year low of $19.17 and a 1 year high of $41.36.
Guardian Pharmacy Services (NYSE:GRDN – Get Free Report) last announced its quarterly earnings results on Wednesday, March 11th. The company reported $0.37 EPS for the quarter, beating analysts’ consensus estimates of $0.27 by $0.10. Guardian Pharmacy Services had a net margin of 3.40% and a return on equity of 31.64%. The business had revenue of $397.62 million for the quarter, compared to analyst estimates of $390.04 million. The business’s revenue for the quarter was up 17.4% on a year-over-year basis. As a group, equities analysts anticipate that Guardian Pharmacy Services, Inc. will post 1.17 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
GRDN has been the subject of several research reports. Raymond James Financial reaffirmed an “outperform” rating and set a $40.00 price target on shares of Guardian Pharmacy Services in a research note on Thursday, March 12th. Wall Street Zen raised Guardian Pharmacy Services from a “buy” rating to a “strong-buy” rating in a report on Saturday, April 25th. UBS Group reissued a “buy” rating on shares of Guardian Pharmacy Services in a report on Thursday, March 12th. Jefferies Financial Group initiated coverage on Guardian Pharmacy Services in a report on Monday, March 30th. They issued a “buy” rating and a $44.00 price objective for the company. Finally, Truist Financial increased their price objective on Guardian Pharmacy Services from $38.00 to $43.00 and gave the company a “buy” rating in a report on Monday, April 13th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $40.50.
View Our Latest Stock Analysis on Guardian Pharmacy Services
About Guardian Pharmacy Services
Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs.
Further Reading
Want to see what other hedge funds are holding GRDN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Guardian Pharmacy Services, Inc. (NYSE:GRDN – Free Report).